Gemini Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 One Kendall Square Cambridge MA United States of America 02139
- IPO Date
- Aug 12, 2020
- CIK
- 0001816736
- Website
- geminitherapeutics.com
- Similar Companies
- Business
- Gemini Therapeutics, Inc. (NASDAQ:GMTX) is a clinical-stage biotechnology company focused on the discovery and development of integrin-targeting therapies for fibrotic diseases; its proprietary antibody discovery platform identifies and optimizes highly selective inhibitors of integrin subunits that activate transforming growth factor-β (TGF-β), a key driver of tissue fibrosis, aiming to block fibrotic signaling at its source for potentially superior safety and efficacy over broader anti-fibrotic agents. The company's lead programs target chronic kidney disease and idiopathic pulmonary fibrosis, with preclinical data demonstrating reduced tissue scarring and preserved organ function; it is advancing top candidates toward investigational new drug (IND) applications while exploring ocular and hepatic fibrosis indications. Founded in 2015 and headquartered in Cambridge, Massachusetts, Gemini Therapeutics collaborates with academic centers and contract research organizations in North America and Europe to support its global preclinical and clinical efforts. In December 2022, Gemini Therapeutics completed a reverse merger with Disc Medicine, Inc., a clinical-stage biopharmaceutical firm developing treatments for hematologic diseases including bitopertin (in-licensed from Roche) for erythropoietic protoporphyria and DISC-0974 for iron overload disorders, resulting in approximately $175 million in cash to fund Disc's pipeline through 2025; the combined entity retained the GMTX ticker and shifted primary focus to Disc's hematology assets while winding down Gemini's prior age-related macular degeneration programs such as GEM103.
Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile
FDA reversals leave investors worrying about the fates of other experimental drugs
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
Gemini Therapeutics (NASDAQ:GMTX) Shares Down 2.6% – What’s Next?
7 Short-Squeeze Stocks for Bold Contrarians to Consider
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. – GMTX
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside
Gemini Therapeutics to Participate in Upcoming Investor Conferences
Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings?
GMTX Stock: Why It Fell This Week
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
3 Biotech Stocks With Big Catalysts in June
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update